Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

Amgen Inc (AMGN) moved down by 8.33%. The Pharmaceuticals & Medical Research sector is down by 2.43%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Johnson & Johnson (JNJ) down 2.00%; Amgen Inc (AMGN) down 8.33%; Eli Lilly and Co (LLY) down 1.99%.

What is driving Amgen Inc (AMGN)’s stock price down today?

Amgen experienced notable downward pressure due to a significant setback in the cardiovascular drug pipeline landscape. Competitor Novartis revealed that its Phase III trial for pelacarsen, an experimental therapy targeting elevated lipoprotein(a), failed to reduce major adverse cardiovascular events despite successfully lowering target lipid levels. This unexpected result rattled market sentiment across the entire lipoprotein(a)-lowering therapeutic class. Because Amgen is actively developing a key late-stage contender, olpasiran, in its own pivotal cardiovascular outcomes study, investors quickly reassessed the probability of success and future commercial viability for Amgen's candidate. The read-across risk introduced unexpected clinical uncertainty into one of the biotech giant's most anticipated pipeline catalysts.

Compounding the clinical sentiment shift, major Wall Street research firms adjusted their ratings and risk parameters on the stock. BMO Capital downgraded Amgen from an Outperform to a Market Perform stance, highlighting that the stock's substantial prior rally had effectively priced in base-case commercial execution while leaving little safety margin for pipeline missteps or looming loss-of-exclusivity headwinds on mature drugs. Additional cautious commentary from analysts pointed to valuation models suggesting the stock had stretched beyond intrinsic cash-flow projections near recent multi-month highs. The convergence of elevated valuation multiples and a newly heightened risk profile prompted institutional portfolio managers to lock in gains and trim allocations.

The severe intraday movement was further amplified by broader market factors, including index-level rebalancing and price-weighted selling pressure within major market benchmarks. While Amgen recently announced positive clinical developments in its oncology franchise, short-term momentum remained dictated by the heightened scrutiny surrounding its cardiovascular pipeline and competitive threats from biosimilars against legacy products. Going forward, institutional investors will closely monitor upcoming clinical readouts from Amgen's proprietary programs to determine whether distinct molecular mechanisms can differentiate its pipeline from competing industry setbacks and restore long-term growth confidence.

Technical Analysis of Amgen Inc (AMGN)

Technically, Amgen Inc (AMGN) shows a MACD (12,26,9) value of -8.423, indicating a neutral signal. The RSI at 40.256 suggests neutral condition and the Williams %R at 97.857 suggests oversold condition. Please monitor closely.

Media Coverage of Amgen Inc (AMGN)

In terms of media coverage, Amgen Inc (AMGN) shows a coverage score of 48, indicating a moderate level of media attention. The overall market sentiment index is currently in extremely bullish zone.

Fundamental Analysis of Amgen Inc (AMGN)

Amgen Inc (AMGN) is in the Pharmaceuticals & Medical Research industry. Its latest annual revenue is $36.75B, ranking 14 in the industry. The net profit is $7.71B, ranking 10 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as Hold, with an average price target of $390.14, a high of $457.00, and a low of $225.00.

More details about Amgen Inc (AMGN)

Company Specific Risks:

• Cardiovascular Pipeline Readout Vulnerability: Novartis's failed Phase III trial evaluating pelacarsen revealed that lowering Lp(a) cholesterol failed to reduce cardiovascular events, triggering severe market skepticism and de-risking around Amgen's competing Phase III candidate, olpasiran, in its ongoing OCEAN(a)-Outcomes study.
• Wall Street Analyst Downgrades: BMO Capital downgraded Amgen from Outperform to Market Perform, warning that commercial execution is already priced in following a 34% year-to-date rally, while JPMorgan analysts noted that olpasiran's commercial potential is now significantly diminished.
• Accelerating Biosimilar Erosion and IRA Price Caps: Mature blockbuster franchises including Prolia, XGEVA, and Enbrel face steep volume declines and pricing pressure driven by new international biosimilar launches and mandatory U.S. Medicare Part D price setting under the Inflation Reduction Act.
• Elevated Options Volatility and Obesity Pipeline Execution Risk: AMGN implied volatility has spiked to the 96th percentile of its annual range as investors price in high binary risk and intense competitive pressures facing obesity candidate MariTide against entrenched market incumbents.